A Pinborg

No ORCID on file · 4 papers in corpus
other 2026
Prevalence of an endogenous LH rise following final GnRH antagonist dose in the IVF antagonist protocol
European journal of obstetrics & gynecology and reproductive biology: X ·doi:10.1016/j.eurox.2026.100454

BACKGROUND: The GnRH antagonist protocol is widely used in IVF/ICSI treatments. It involves daily injections of a GnRH antagonist starting on stimulation day 5 or later to prevent premature ovulation by suppressing the endogenous gonadotrop…

observational 2019
Assisted reproductive technology treatment and risk of ovarian cancer-a nationwide population-based cohort study
Human Reproduction ·doi:10.1093/humrep/dez165

STUDY QUESTION: Does hormone stimulation during assisted reproductive technology (ART) treatment increase the risk of ovarian cancer? SUMMARY ANSWER: No increased risk of ovarian cancer was found among ART-treated women, with the exception…

observational 2019
Prediction of the lower serum anti-Müllerian hormone threshold for ovarian stimulation prior to in-vitro fertilization using the Elecsys® AMH assay: a prospective observational study
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-019-0452-4

BACKGROUND: In assisted reproductive technology, prediction of treatment failure remains a great challenge. The development of more sensitive assays for measuring anti-Müllerian hormone (AMH) has allowed for the possibility to investigate i…

rct 2009
Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study
Human Reproduction ·doi:10.1093/humrep/dep239

BACKGROUND: Controlled ovarian stimulation (COS) and intrauterine insemination (IUI) are often used as the first-line treatment for subfertile couples. To minimize the variability in ovarian response in patients' first treatment cycle, we r…